BRPI0916366A2 - exame diagnóstico de anticorpo - Google Patents

exame diagnóstico de anticorpo

Info

Publication number
BRPI0916366A2
BRPI0916366A2 BRPI0916366A BRPI0916366A BRPI0916366A2 BR PI0916366 A2 BRPI0916366 A2 BR PI0916366A2 BR PI0916366 A BRPI0916366 A BR PI0916366A BR PI0916366 A BRPI0916366 A BR PI0916366A BR PI0916366 A2 BRPI0916366 A2 BR PI0916366A2
Authority
BR
Brazil
Prior art keywords
diagnostic test
antibody diagnostic
antibody
test
diagnostic
Prior art date
Application number
BRPI0916366A
Other languages
English (en)
Inventor
Reisenauer-Schaupp Anita
Demuth Hans-Ulrich
Rahfeld Jens-Ulrich
Gans Kathrin
Kleinschmidt Martin
Kampfer Sonja
Schilling Stephan
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of BRPI0916366A2 publication Critical patent/BRPI0916366A2/pt
Publication of BRPI0916366B1 publication Critical patent/BRPI0916366B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0916366-2A 2008-07-21 2009-07-10 Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma BRPI0916366B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8230908P 2008-07-21 2008-07-21
DE61/082,309 2008-07-21
PCT/EP2009/058803 WO2010009987A2 (en) 2008-07-21 2009-07-10 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
BRPI0916366A2 true BRPI0916366A2 (pt) 2018-05-29
BRPI0916366B1 BRPI0916366B1 (pt) 2021-08-10

Family

ID=41059893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916366-2A BRPI0916366B1 (pt) 2008-07-21 2009-07-10 Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma

Country Status (15)

Country Link
US (3) US8058405B2 (pt)
EP (4) EP2320942B1 (pt)
JP (2) JP5828762B2 (pt)
KR (1) KR101706789B1 (pt)
CN (2) CN102131519B (pt)
AU (1) AU2009273387B9 (pt)
BR (1) BRPI0916366B1 (pt)
CA (1) CA2731044C (pt)
EA (1) EA028427B1 (pt)
HK (1) HK1222397A1 (pt)
IL (1) IL210225A (pt)
MX (1) MX2011000875A (pt)
NZ (1) NZ590563A (pt)
WO (1) WO2010009987A2 (pt)
ZA (1) ZA201100178B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
LT3339323T (lt) 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
AU2012228236B2 (en) * 2011-03-16 2016-10-27 Vivoryon Therapeutics N.V. Diagnostic antibody assay
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
PT3663317T (pt) 2012-08-21 2023-01-23 Janssen Pharmaceutica Nv Anticorpos para haptenos de quetiapina e sua utilização
WO2014031668A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine and use thereof
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
CN104755093B (zh) 2012-08-21 2018-11-16 詹森药业有限公司 奥氮平半抗原的抗体及其用途
ES2822914T3 (es) 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
JP2017513030A (ja) * 2014-04-04 2017-05-25 オートテリック エルエルシー パクリタキセルの薬物動態ガイド下投薬のための血漿中パクリタキセル濃度のモニタリングのための方法、デバイス、および試薬
US9714953B2 (en) 2014-04-04 2017-07-25 Autotelic Llc Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
US10758612B2 (en) 2015-07-15 2020-09-01 Washington University Antibodies to tumor associated complex N-glycans with terminal GlcNAcβ residues and methods of use thereof
JP7002811B2 (ja) * 2015-07-16 2022-03-04 ビボリョン セラピューティクス エヌブイ 抗ピログルタミン酸化アミロイドβヒト化抗体
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
AU2016370853A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
WO2020193644A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
WO2021180782A1 (en) 2020-03-10 2021-09-16 Lifearc Cyclic peptides
US20240116985A1 (en) * 2020-07-22 2024-04-11 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
CA3236504A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
PE20241471A1 (es) 2021-10-29 2024-07-17 Lilly Co Eli Compuestos y metodos dirigidos a la interleucina-34
KR20240099348A (ko) 2021-10-29 2024-06-28 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
IL321331A (en) 2022-12-22 2025-08-01 Bioarctic Ab Antibody that binds to ABETAPE3
US20250388664A1 (en) 2024-06-20 2025-12-25 Bioarctic Ab Bispecific binding molecule
CN121324641A (zh) * 2025-12-15 2026-01-13 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种检测内罗毕羊病病毒的试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US20040241164A1 (en) * 2001-08-17 2004-12-02 Bales Kelly Renee Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
PL377769A1 (pl) 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
ATE462432T1 (de) * 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
EP1961416B1 (en) * 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
PL2074145T3 (pl) 2006-10-02 2017-11-30 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
JP5456479B2 (ja) 2006-11-09 2014-03-26 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
EP2086960B1 (en) 2006-11-09 2014-03-05 Probiodrug AG Novel inhibitors of glutaminyl cyclase
EP2091948B1 (en) * 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
JP5612860B2 (ja) 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体
US8772508B2 (en) 2007-04-18 2014-07-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008128986A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
US9034907B2 (en) 2007-04-18 2015-05-19 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8227498B2 (en) 2007-04-18 2012-07-24 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5676249B2 (ja) 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
AU2008297070A1 (en) 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
CN102027548B (zh) * 2008-04-29 2014-01-01 桑迪士克以色列有限公司 具有用于编程、验证和读取的参考电压电平的适应性设置的非易失性多电平存储器

Also Published As

Publication number Publication date
CA2731044C (en) 2020-07-14
JP6307483B2 (ja) 2018-04-04
JP2016028064A (ja) 2016-02-25
JP5828762B2 (ja) 2015-12-09
AU2009273387B2 (en) 2014-12-04
WO2010009987A3 (en) 2010-05-20
EP2320942B1 (en) 2018-03-14
EP3047854B1 (en) 2018-03-21
US9676843B2 (en) 2017-06-13
CN102131519A (zh) 2011-07-20
EP2320942A2 (en) 2011-05-18
CN105481980A (zh) 2016-04-13
IL210225A0 (en) 2011-03-31
EA028427B1 (ru) 2017-11-30
HK1158946A1 (zh) 2012-07-27
EP3338795A1 (en) 2018-06-27
CN102131519B (zh) 2016-01-13
KR20110031989A (ko) 2011-03-29
AU2009273387A1 (en) 2010-01-28
IL210225A (en) 2015-09-24
EP3047854A1 (en) 2016-07-27
AU2009273387B9 (en) 2015-06-11
CA2731044A1 (en) 2010-01-28
HK1222397A1 (zh) 2017-06-30
JP2011528561A (ja) 2011-11-24
ZA201100178B (en) 2012-02-29
EA201100231A1 (ru) 2011-08-30
US20160053001A1 (en) 2016-02-25
NZ590563A (en) 2012-06-29
MX2011000875A (es) 2011-04-05
BRPI0916366B1 (pt) 2021-08-10
US20120064547A1 (en) 2012-03-15
US20100021478A1 (en) 2010-01-28
KR101706789B1 (ko) 2017-02-14
EP3338796A1 (en) 2018-06-27
US8058405B2 (en) 2011-11-15
US9156907B2 (en) 2015-10-13
WO2010009987A2 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
BRPI0916366A2 (pt) exame diagnóstico de anticorpo
EP2335041A4 (en) VEHICLE TEST ARRANGEMENT
BRPI0915675A2 (pt) Aparelho de medição
PT3072906T (pt) Formulação de anticorpos
BRPI0922800A2 (pt) anticorpos c-met
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI1006519A2 (pt) formulação de anticorpos
EP4024013C0 (en) ANALYSIS SYSTEM
EP2433007A4 (en) DIAGNOSTIC SYSTEM
IT1397120B1 (it) Dispositivo integrato per analisi diagnostiche, e relativo procedimento
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
IL212175B (en) Muc1* antibodies
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
BRPI0921997A2 (pt) dispositivo para medição do componente de sangue.
EP2300828A4 (en) SCREENING SYSTEM FOR ANTIGENS
AT10812U2 (de) Prüfstandsanordnung
AT10813U2 (de) Prüfstandsanordnung
EP2402875A4 (en) Noise analysis design method
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BR112012004102A2 (pt) métodos de ensaio
DK2930516T3 (da) Graviditetstest
IT1397673B1 (it) Provetta per analisi diagnostiche
FI20085881A0 (fi) Testiadapterikonfiguraatio
BRPI0813440A2 (pt) Dispositivo de medição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS AG (DE)

B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS N.V. (DE)